Formycon AG (ETR:FYB)
Germany
· Delayed Price · Currency is EUR | Market Cap | 318.47M |
| Revenue (ttm) | 44.48M |
| Net Income (ttm) | -64.70M |
| Shares Out | 17.67M |
| EPS (ttm) | -3.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,042 |
| Average Volume | 10,561 |
| Open | 17.88 |
| Previous Close | 18.02 |
| Day's Range | 17.58 - 17.88 |
| 52-Week Range | 15.80 - 31.30 |
| Beta | 0.67 |
| RSI | 43.99 |
| Earnings Date | May 28, 2026 |
About Formycon AG
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company’s pipeline includes ustekinumab used in the treatment of Crohn’s disease, ulcerative colitis... [Read more]
Financial Performance
In 2025, Formycon AG's revenue was 44.48 million, a decrease of -36.17% compared to the previous year's 69.67 million. Losses were -64.70 million, -48.52% less than in 2024.
Financial StatementsNews
Formycon AG (XTER:FYB) Full Year 2025 Earnings Call Highlights: Transformational Year with ...
Formycon AG (XTER:FYB) Full Year 2025 Earnings Call Highlights: Transformational Year with Strategic Growth and Challenges
Full Year 2025 Formycon AG Earnings Call Transcript
Full Year 2025 Formycon AG Earnings Call Transcript
Formycon AG Earnings Call Transcript: Q4 2025
2025 saw a strategic transformation with improved adjusted EBITDA and strong cost management, despite lower revenues. 2026 guidance anticipates significant revenue growth, driven by FYB202 royalties and FYB206 milestones, with positive EBITDA expected.
EQS-News: Formycon reports successful financial year 2025 with important operational progress, growing market presence and strategic partnerships
EQS-News: Formycon AG / Key word(s): Annual Report/Forecast Formycon reports successful financial year 2025 with important operational progress, growing market presence and strategic partnerships 22.0...
EQS-News: Formycon invites to Conference Call on the Results of the Financial Year 2025 and announces Participation in international Investor Conferences in the 2nd Quarter of 2026
EQS-News: Formycon AG / Key word(s): Miscellaneous Formycon invites to Conference Call on the Results of the Financial Year 2025 and announces Participation in international Investor Conferences in th...
EQS-AFR: Formycon AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQS Preliminary announcement financial reports: Formycon AG / Preliminary announcement on the disclosure of financial statements Formycon AG: Preliminary announcement of the publication of financial r...
Formycon AG: Unlocking Breakthrough Biotech Innovations
The company reports a marked EBITDA recovery, stable revenues, and higher working capital, while confirming its FYB202 assessment and setting the stage for the 2026 outlook.
EQS-Adhoc: Formycon AG:
EQS-Ad-hoc: Formycon AG / Key word(s): Results / Full year/Other Formycon AG: 15-Apr-2026 / 19:52 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014...
Formycon Secures Europe Launch Timing For FYB203 After Regeneron, Bayer Settlement
(RTTNews) - Formycon AG (FYB.DE, FYBGF), an independent German biotechnology company, on Thursday announced that it entered into a settlement and license agreement with Regeneron Pharmaceuticals, Inc....
EQS-News: Formycon secures license date for aflibercept 2 mg biosimilar FYB203 in Europe and further territories following settlement with Regeneron and Bayer
EQS-News: Formycon AG / Key word(s): Miscellaneous Formycon secures license date for aflibercept 2 mg biosimilar FYB203 in Europe and further territories following settlement with Regeneron and Bayer ...
EQS-Adhoc: Formycon AG postpones the publication of its audited annual and consolidated financial statements for 2025
EQS-Ad-hoc: Formycon AG / Key word(s): Annual Report / Postponement of the publication/Annual Report / Postponement of the publication Formycon AG postpones the publication of its audited annual and c...
EQS-Adhoc: Formycon AG publishes preliminary figures for the 2025 fiscal year
EQS-Ad-hoc: Formycon AG / Key word(s): Results / Full year/Other Formycon AG publishes preliminary figures for the 2025 fiscal year 04-March-2026 / 22:50 CET/CEST Disclosure of an inside information a...
EQS-News: Formycon announces positive clinical data for Keytruda biosimilar candidate FYB206 (pembrolizumab)
EQS-News: Formycon AG / Key word(s): Study results/Study Formycon announces positive clinical data for Keytruda biosimilar candidate FYB206 (pembrolizumab) 25.02.2026 / 06:30 CET/CEST The issuer is so...
EQS-News: Lotus Pharmaceutical becomes commercialization partner for Formycon's Keytruda biosimilar candidate FYB206 across major parts of the Asia-Pacific Region
EQS-News: Formycon AG / Key word(s): Agreement Lotus Pharmaceutical becomes commercialization partner for Formycon's Keytruda biosimilar candidate FYB206 across major parts of the Asia-Pacific Region ...
EQS-DD: Formycon AG: Active Ownership Fund SICAV SIF SCS, sell
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 13.01.2026 / 01:04 CET/CEST The issuer is solely responsi...
EQS-DD: Formycon AG: Active Ownership Fund SICAV SIF SCS, Verkauf • news
EQS-News: FDA approves another interchangeable Ranibizumab Biosimilar, Nufymco – Strengthening US Presence with Zydus as Commercialization Partner
EQS-News: Formycon AG / Key word(s): Regulatory Approval/Alliance FDA approves another interchangeable Ranibizumab Biosimilar, Nufymco – Strengthening US Presence with Zydus as Commercialization Partn...
Formycon AG: Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada
Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a strong foundation for a successful launch of FYB206Strong early partneri...
Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada
Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a strong foundation for a successful launch of FYB206 Strong early partnering ...
EQS-News: Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada
EQS-News: Formycon AG / Key word(s): Alliance/Agreement Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Can...
Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda biosimilar candidate FYB206 for the MENA Region
PLANEGG-MARTINSRIED, Germany and AMMAN, Jordan, Dec. 4, 2025 /PRNewswire/ -- Formycon AG (FSE: FYB, Prime Standard) and MS Pharma jointly announce that they have entered into an exclusive licensin...
Formycon, MS Pharma Sign Commercialization Partnership For Keytruda Biosimilar
(RTTNews) - Formycon AG (FYB.DE) and MS Pharma have entered into an exclusive licensing and supply agreement for the commercialization of FYB206, Formycon's biosimilar candidate to Keytruda, in the Mi...
EQS-News: Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda biosimilar candidate FYB206 for the MENA Region
EQS-News: Formycon AG / Key word(s): Agreement Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda biosimilar candidate FYB206 for the MENA Region 04.12.2025 / 06:30 CET/C...
EQS-News: NTC becomes commercialization partner for Formycon’s Eylea biosimilar FYB203/Baiama in Italy
EQS-News: Formycon AG / Key word(s): Miscellaneous NTC becomes commercialization partner for Formycon’s Eylea biosimilar FYB203/Baiama in Italy 24.11.2025 / 06:30 CET/CEST The issuer is solely respons...